ArticleBMC pregnancy and childbirth2026
Serum visinin-like protein-1 levels in preeclampsia: a cross-sectional pilot study.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate serum Visinin-like protein-1 (VILIP-1) levels in normotensive pregnant women and in patients with preeclampsia across the severity spectrum, and to investigate the association between VILIP-1 levels and disease severity.
methodsIn this prospective cross-sectional pilot study, a total of 60 pregnant women were allocated into three groups: normotensive controls (n = 20), preeclampsia without severe features (n = 20), and preeclampsia with severe features (n = 20). Baseline clinical and laboratory characteristics were recorded. Serum VILIP-1 levels were measured and compared among groups. Statistical analyses were performed using non-parametric tests with adjustment for multiple comparisons.
resultsBaseline demographic and obstetric characteristics were comparable among groups. Gestational age at delivery and neonatal birth weight were significantly lower in the preeclampsia with severe features group. Markers of hepatic and renal dysfunction were significantly elevated in this group, whereas hematological parameters did not differ significantly. Serum VILIP-1 levels were significantly higher in patients with preeclampsia with severe features compared with both normotensive pregnant women and those with preeclampsia without severe features (24.75 ± 18.27 ng/mL vs. 10.23 ± 7.98 ng/mL and 7.91 ± 4.97 ng/mL, respectively; adjusted p < 0.05).
conclusionsSerum VILIP-1 levels are significantly increased in preeclampsia with severe features and appear to be associated with disease severity and maternal organ involvement. These findings suggest that VILIP-1 may reflect disease severity rather than serving as a diagnostic biomarker; however, larger prospective studies are warranted to clarify its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.